Red-Hot Biotechs to Take Spotlight at Blood Disorder Meeting

High-flying drug developers that have surged in the face of the ongoing coronavirus pandemic will be in focus starting this weekend at the year’s last big medical meeting, putting surging stocks under the microscope for investors who have cheered massive gains.

Updated results from Trillium Therapeutics Inc., which has boomed 1,550% this year, will be among those most closely watched by Wall Street at the American Society of Hematology (ASH) meeting that kicks off Saturday.